AMGN vs RGEN · P/E 24, rev $10.05B vs P/E 143, rev $204.1M
Amgen Inc (AMGN) versus Repligen Corporation (RGEN) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Repligen Corporation (RGEN) is a medical instruments & supplies company listed on NASDAQ.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported RGEN revenue for 2026-06-30 was $204.1M. Net income was $5.0M. Revenue was up 5.1% from 2026-03-31 to 2026-06-30. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. RGEN currently screens at market cap $7.43B and trailing P/E 143.1.
Not investment advice. Open the AMGN and RGEN stock pages for the full models.
Not investment advice.